Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDH2 | P40926 | 2/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | HPGD | P15428 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.62 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.62 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.62 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2811774 | 0.92 | ALDH1A1 (0.66) | MDH2ALDH1A1HPGDSMN1; SMN2GABRA1 | |
| SCHEMBL4906659 | 0.91 | GABRA1 (0.71) | MDH2ALDH1A1HPGDSMN1; SMN2GABRA1 | |
| SCHEMBL4030619 | 0.85 | TRPM8 (0.63) | MDH2ALDH1A1HPGDSMN1; SMN2GABRA1 | |
| SCHEMBL5161582 | 0.84 | GABRA1 (0.64) | MDH2ALDH1A1HPGDSMN1; SMN2GABRA1 | |
| SCHEMBL4486238 | 0.83 | ALDH1A1 (0.64) | MDH2ALDH1A1HPGDSMN1; SMN2GABRA1 | |
| SCHEMBL5159020 | 0.83 | GABRA1 (0.62) | MDH2ALDH1A1HPGDSMN1; SMN2GABRA1 | |
| SCHEMBL2977304 | 0.83 | GABRA1 (0.62) | ALDH1A1HPGDGABRA1GABRB2GABRB1 | |
| SCHEMBL11403307 | 0.82 | GABRA1 (0.56) | MDH2ALDH1A1HPGDSMN1; SMN2GABRA1 | |
| SCHEMBL16714028 | 0.81 | MDH2 (0.85) | MDH2ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL11142732 | 0.81 | GABRA1 (0.69) | MDH2ALDH1A1HPGDSMN1; SMN2GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062218-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| US-20080249033-A1 | Carbamate Linked Macrolides Useful For The Treatment Of Microbial Infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O. (HR) | 2008-10-09 | — | — | US | disclosed |
| US-20070213283-A1 | Macrolides substituted at the 4\"-position | GLAXO GROUP LIMITED (GB) | 2007-09-13 | — | — | US | disclosed |
| EP-1824871-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-29 | — | — | EP | disclosed |
| CN-1980945-A | Carbamate linked macrolides useful for the treatment of microbial infections | GLAXOSMITHKLINE ZAGREB (HR) | 2007-06-13 | — | — | CN | disclosed |
| WO-2006050940-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
| EP-1625137-A1 | MACROLIDES SUBSTITUTED AT THE 4''-POSITION | GLAXO GROUP LIMITED (GB) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004101585-A1 | MACROLIDES SUBSTITUDED AT THE 4'-POSITION | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213283-A1 | Macrolides substituted at the 4\"-position | IL4, CYP51A1, IL17A | MDH2 2286/4885ALDH1A1 2288/4885HPGD 2689/4885 |
| US-20090062218-A1 | MACROLONE COMPOUNDS | CYP51A1, MRPL21, MYD88 | MDH2 1469/4885ALDH1A1 4011/4885HPGD 2617/4885 |
| US-20080249033-A1 | Carbamate Linked Macrolides Useful For The Treatment Of Microbial Infections | CYP51A1, CUTA, MALT1 | MDH2 3152/4885ALDH1A1 3491/4885HPGD 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.